Request Demo
Last update 03 Nov 2025
Tilpisertib Fosmecarbil
Last update 03 Nov 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms GS 5290, GS-5290, GS5290 |
Target |
Action inhibitors |
Mechanism TPL2 inhibitors(Mitogen-activated protein kinase kinase kinase 8 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC35H36ClN8O7P |
InChIKeyFPQIBCPWXJSFOQ-ILNPBIMBSA-N |
CAS Registry2567459-64-5 |
Related
2
Clinical Trials associated with Tilpisertib FosmecarbilCTIS2022-501119-14-01
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis - GS-US-457-6411
NCT06029972
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis
100 Clinical Results associated with Tilpisertib Fosmecarbil
Login to view more data
100 Translational Medicine associated with Tilpisertib Fosmecarbil
Login to view more data
100 Patents (Medical) associated with Tilpisertib Fosmecarbil
Login to view more data
100 Deals associated with Tilpisertib Fosmecarbil
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colitis, Ulcerative | Phase 2 | United States | 05 Dec 2023 | |
| Colitis, Ulcerative | Phase 2 | Japan | 05 Dec 2023 | |
| Colitis, Ulcerative | Phase 2 | Australia | 05 Dec 2023 | |
| Colitis, Ulcerative | Phase 2 | Austria | 05 Dec 2023 | |
| Colitis, Ulcerative | Phase 2 | Belgium | 05 Dec 2023 | |
| Colitis, Ulcerative | Phase 2 | Canada | 05 Dec 2023 | |
| Colitis, Ulcerative | Phase 2 | France | 05 Dec 2023 | |
| Colitis, Ulcerative | Phase 2 | Germany | 05 Dec 2023 | |
| Colitis, Ulcerative | Phase 2 | Hungary | 05 Dec 2023 | |
| Colitis, Ulcerative | Phase 2 | Italy | 05 Dec 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free